Mirion Technologies, Inc. provides radiation detection, measurement, analysis, and monitoring products and services in North America, Europe, and the Asia Pacific. It operates in two segments, Medical, and Nuclear & Safety. The Medical segment offers radiation oncology quality assurance and dosimetry solutions; patient safety solutions for diagnostic imaging and radiation therapy centers; radiation therapy quality assurance solutions for calibrating and verifying imaging and treatment accuracy; and radionuclide therapy products for nuclear medicine applications, such as product handling, medical imaging furniture, and rehabilitation products. This segment improves the quality and safety of cancer care delivery; and supports applications across medical diagnostics and practitioner safety. The Nuclear & Safety segment focuses on addressing critical radiation safety, measurement, and analysis applications; and provides personal radiation detection, identification equipment, and analysis tools. The company's products and solutions also include radiation measurement and monitoring solutions, reactor instrumentation and control detectors, imaging systems and cameras, and waste management systems; laboratory and scientific analysis systems comprising gamma/alpha spectroscopy, alpha/beta counting, specialty detectors, and spectroscopy software; radiation measurement and health physics instrumentation; and contamination and clearance monitors. It serves hospitals, clinics and urgent care facilities, dental and veterinary offices, radiation treatment facilities, OEMs for radiation therapy, laboratories, military organizations, government agencies, industrial companies, power and utility companies, reactor design firms, and NPPs. The company was formerly known as Global Monitoring Systems, Inc. and changed its name to Mirion Technologies, Inc. in January 2006. Mirion Technologies, Inc. was incorporated in 2005 and is headquartered in Atlanta, Georgia.

Mirion Technologies Inc. Class A

Mirrabooka Investments Ltd ( ($AU:MIR) ) just unveiled an announcement. Mirrabooka Investments Limited has announced that it will present its half-...

Mirrabooka to Present 2025/26 Half-Year Results via Investor Webcast

The latest update is out from Mirrabooka Investments Ltd ( ($AU:MIR) ). Mirrabooka reported a pre-tax net tangible asset (NTA) backing of $3.18 per...

Mirrabooka Posts Slightly Lower NTA as Interim Dividend Provision Takes Effect

An update from Mirrabooka Investments Ltd ( ($AU:MIR) ) is now available. Mirrabooka Investments Limited has updated its earlier dividend notificat...

Mirrabooka Sets DRP and DSSP Price at $3.05 for Interim Dividend

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Mirum Pharmaceuticals (MIRM – Research Report), RE...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Mirum Pharmaceuticals (MIRM), REPRO-MED Systems (KRMD) and Alcon (ALC)

In a report released yesterday, Gavin Clark-Gartner from Evercore ISI reiterated a Buy rating on Mirum Pharmaceuticals, with a price target of $101...

Evercore ISI Keeps Their Buy Rating on Mirum Pharmaceuticals (MIRM)

Mirrabooka Investments Ltd ( ($AU:MIR) ) has shared an update. Mirrabooka Investments Limited has declared an interim dividend of AUD 0.045 per ord...

Mirrabooka Declares Interim Dividend of 4.5 Cents per Share

Mirrabooka Investments Ltd ( ($AU:MIR) ) just unveiled an announcement. Mirrabooka Investments Limited has reported an estimated pre-tax net tangib...

Mirrabooka Posts Estimated Pre-Tax NTA of $3.28 Per Share

Mirrabooka Investments Ltd ( ($AU:MIR) ) has issued an update. Mirrabooka reported that its net tangible asset backing per share fell over December...

Mirrabooka’s NTA Slips in December as Small and Mid-Cap Portfolio Holds Course

Mirrabooka Investments Ltd ( ($AU:MIR) ) has issued an announcement. Mirrabooka Investments Limited has reported an estimated pre-tax net tangible ...

Current Quarter	$0.15	Next Quarter	$0.11
Current Year	$0.44	Next Year	$0.55
QoQ Growth	-26.7%	YoY Growth	+25.0%
3Y EPS CAGR	-21.6%	Target Price	$30.33
Consensus	Buy	Upside	+21.7%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	MIR	$24.93	+0.36%	3.61M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	MIR	$24.93	+0.4%	3.61M
3
4
5
6

MIR

MIR

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Mirion Technologies Inc. Class A Data in Excel

Get Mirion Technologies Inc. Class A Data in Excel